SEOUL, Oct. 28 (Yonhap) -- Yuhan Corp., a South Korean biopharmaceutical company, said Monday its third-quarter net profit ...

Yuhan-Kimberly, a joint venture between Korea’s Yuhan Corp. and America’s Kimberly Clark, has been chosen as one of the ...

Gilead Sciences has abandoned a liver disease collaboration with Yuhan. A new study suggests Leqembi's vial design could cost Medicare hundreds of millions of dollars in waste each year.

Gilead Sciences Inc. terminated a potential $785 million licensing deal with Yuhan Corp. inked in 2019 to develop metabolic dysfunction-associated steatohepatitis (MASH) therapies. BioWorld Asia Deals ...

J INTS BIO will oversee the entire project, managing clinical trials to validate AI-based predictions and develop clinically ...

Shim Jae-jeong, a professor of respiratory and allergy at Korea University Guro Hospital, won the 'limited tuberculosis and ...

Yuhan Li is Associate Director of Learning Design in the Center for Digital Innovation in Learning at Boston College. With nearly 8 years of experience supporting faculty teaching in higher education, ...